ADHD

Pipeline Programs

Companies

Clinical Trials

4 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule

2100%

+ 39 programs with unclassified modality

On Market (1)

Approved therapies currently available

DAYTRANAApproved

methylphenidate

Noven Pharmaceuticals

Central Nervous System Stimulant [EPC]transdermal2006

429K Part D

Competitive Landscape

22 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

Prevail TherapeuticsNY - New York

4 programs

AtomoxetinePhase 41 trial

Atomoxetine HydrochloridePhase 41 trial

atomoxetinePhase 41 trial

AtomoxetineN/A1 trial

Active Trials

NCT00540826Completed518Est. Jun 2009

NCT00190957Completed140Est. Jan 2006

NCT00190736Completed440Est. Sep 2006

+1 more trials

Human BioSciencesWV - Martinsburg

3 programs

MethylphenidatePhase 41 trial

Atomoxetine HydrochlorideN/A1 trial

Genetic Analysis of Attention Deficit Hyperactivity Disorder (ADHD)N/A1 trial

Active Trials

NCT03154359Completed51Est. Jun 2022

NCT00046059Completed3,481Est. Jan 2020

NCT03781752Recruiting500Est. Aug 2025

Angeles TherapeuticsCA - Los Angeles

3 programs

Randomization to either AmphetaminePhase 41 trial

Brainsonix Pulsar 1002N/A1 trial

Flashed Light TherapyN/A1 trial

Active Trials

NCT04497363Unknown100Est. Mar 2026

NCT06036420Active Not Recruiting6Est. Mar 2027

NCT05916339Recruiting500Est. Dec 2027

Noven PharmaceuticalsFL - Miami

2 programs

Methylphenidate Transdermal SystemPhase 31 trial

methylphenidate transdermal systemPhase 31 trial

Active Trials

NCT00501293Completed163Est. Feb 2009

NCT00499863Completed217Est. May 2008

PfizerNEW YORK, NY

1 program

Very Low Dose Quillivant XRPhase 41 trial

Active Trials

NCT02255565Completed36Est. Oct 2016

OtsukaJapan - Tokushima

3 programs

CentanafadinePhase 31 trial

BrexpiprazolePhase 1Small Molecule1 trial

CentanafadinePhase 11 trial

Active Trials

NCT03292848Completed24Est. May 2018

NCT07314333Recruiting42Est. Apr 2026

NCT06973577Active Not Recruiting315Est. Apr 2026

Purdue PharmaCT - Stamford

3 programs

Drug: PRC-063Phase 31 trial

PRC-063 oral capsulesPhase 31 trial

Active Trials

NCT02168127Completed360Est. Jun 2015

NCT03618030Completed288Est. Jul 2019

NCT03172481Completed156Est. Dec 2017

SandozAustria - Kundl

3 programs

Focalin XRPhase 31 trial

Methylphenidate hydrochloridePhase 31 trial

Active Trials

NCT00141050Completed90Est. Jul 2005

NCT00141063Completed90Est. Aug 2005

NCT00254878Completed130Est. Feb 2006

Colorado TherapeuticsCO - Louisville

1 program

MethylphenidatePhase 31 trial

Active Trials

NCT00264797Completed303Est. Oct 2008

BiocorpFrance - Issoire

1 program

Cannabis oilPhase 21 trial

Active Trials

NCT05219370Terminated8Est. Dec 2022

LundbeckDenmark - Copenhagen

1 program

BrexpiprazolePhase 1Small Molecule

Theravance BiopharmaCA - South SF

1 program

TD-9855Phase 11 trial

Active Trials

NCT01924143Completed6Est. Dec 2013

Lumos PharmaTX - Austin

2 programs

ADHD TherapyN/A1 trial

Active Trials

NCT05805176Active Not Recruiting194Est. Jun 2025

NCT05296473Completed560Est. Mar 2024

Jerusalem PharmaceuticalsIsrael - Ramallah

2 programs

CogFun RG occupational therapyN/A1 trial

tDCSN/A1 trial

Active Trials

NCT06639139Recruiting40Est. Feb 2026

NCT03104972Completed47Est. Jan 2022

TakedaTOKYO, Japan

2 programs

SPD544PHASE_11 trial

Mixed amphetamine saltsPHASE_41 trial

Active Trials

NCT01183234Completed28Est. Oct 2010

NCT00506727Completed215Est. Jul 2004

NeurocentriaCA - Walnut Creek

2 programs

NRCT-101SR, NRCT-202XRPHASE_21 trial

NRCT-101-SRPHASE_2_31 trial

Active Trials

NCT06673368Terminated2Est. Jul 2025

NCT05683249Completed223Est. Jan 2024

Zevra TherapeuticsDenmark - Frederiksberg

2 programs

KP415 oral capsulePHASE_31 trial

Active Trials

NCT03460652Completed282Est. Jul 2019

NCT03292952Completed155Est. May 2018

Genome & CompanyKorea - Suwon

1 program

Genetic Analysis of Attention Deficit Hyperactivity Disorder (ADHD)N/A

Innovation PharmaceuticalsMA - Wakefield

1 program

Physical activity with engaging cognitivelyN/A1 trial

Active Trials

NCT06303674Unknown60Est. Sep 2025

SoomaFinland - Helsinki

1 program

transcranial direct current stimulationN/A1 trial

Active Trials

NCT06766214Completed30Est. Feb 2026

NovartisBASEL, Switzerland

1 program

Focalin XRPHASE_3

TevaIsrael - Petach Tikva

1 program

ModafinilPHASE_31 trial

Active Trials

NCT00228540CompletedEst. Sep 2006

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

2027

Angeles TherapeuticsRandomization to either Amphetamine

Human BioSciencesMethylphenidate

PfizerVery Low Dose Quillivant XR

Prevail Therapeuticsatomoxetine

Prevail TherapeuticsAtomoxetine Hydrochloride

Prevail TherapeuticsAtomoxetine

TakedaMixed amphetamine salts

OtsukaCentanafadine

Purdue PharmaPRC-063 oral capsules

Zevra TherapeuticsKP415 oral capsule

Purdue PharmaPRC-063 oral capsules

Purdue PharmaDrug: PRC-063

Noven PharmaceuticalsMethylphenidate Transdermal System

Noven Pharmaceuticalsmethylphenidate transdermal system

Showing 15 of 38 trials with date data

Clinical Trials (38)

Total enrollment: 9,830 patients across 38 trials

NCT05916339 Angeles TherapeuticsRandomization to either Amphetamine

AWARE: Management of ADHD in Autism Spectrum Disorder

Start: Oct 2023Est. completion: Dec 2027500 patients

Phase 4Recruiting

NCT03781752 Human BioSciencesMethylphenidate

Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD

Start: Mar 2018Est. completion: Aug 2025500 patients

Phase 4Recruiting

NCT02255565 PfizerVery Low Dose Quillivant XR

Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study

Start: Sep 2014Est. completion: Oct 201636 patients

Phase 4Completed

NCT00181948 Prevail Therapeuticsatomoxetine

Strattera Treatment in Children With ADHD Who Have Poor Response to Stimulant Therapy

Start: Sep 2004Est. completion: Sep 200730 patients

Phase 4Completed

NCT00190736 Prevail TherapeuticsAtomoxetine Hydrochloride

Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months)

Start: Sep 2004Est. completion: Sep 2006440 patients

Phase 4Completed

NCT00190957 Prevail TherapeuticsAtomoxetine

Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse

Start: Aug 2004Est. completion: Jan 2006140 patients

Phase 4Completed

NCT00506727 TakedaMixed amphetamine salts

Analog Classroom Study Comparison of ADDERALL XR With STRATTERA in Children Aged 6-12 With ADHD

Start: Aug 2003Est. completion: Jul 2004215 patients

Phase 4Completed

NCT06973577 OtsukaCentanafadine

P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety

Start: Mar 2025Est. completion: Apr 2026315 patients

Phase 3Active Not Recruiting

NCT03618030 Purdue PharmaPRC-063 oral capsules

PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Start: Aug 2018Est. completion: Jul 2019288 patients

Phase 3Completed

NCT03460652 Zevra TherapeuticsKP415 oral capsule

KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD

Start: Mar 2018Est. completion: Jul 2019282 patients

Phase 3Completed

NCT03292952 Zevra TherapeuticsKP415 oral capsule

KP415 Classroom Study in Children (6-12 Years of Age) With ADHD

Start: Dec 2017Est. completion: May 2018155 patients

Phase 3Completed

NCT03172481 Purdue PharmaPRC-063 oral capsules

PRC-063 Classroom Study in Children (6-12 Years of Age) With ADHD

Start: May 2017Est. completion: Dec 2017156 patients

Phase 3Completed

NCT02168127 Purdue PharmaDrug: PRC-063

Long-Term Safety of PRC-063 in Adolescents and Adults With ADHD

Start: May 2014Est. completion: Jun 2015360 patients

Phase 3Completed

NCT00501293 Noven PharmaceuticalsMethylphenidate Transdermal System

Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD

Start: Aug 2007Est. completion: Feb 2009163 patients

Phase 3Completed

NCT00499863 Noven Pharmaceuticalsmethylphenidate transdermal system

Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD

Start: Jul 2007Est. completion: May 2008217 patients

Phase 3Completed

NCT00264797 Colorado TherapeuticsMethylphenidate

Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents With Substance Use Disorders (SUD)

Start: Feb 2006Est. completion: Oct 2008303 patients

Phase 3Completed

NCT00254878 SandozMethylphenidate hydrochloride

Placebo-Controlled Comparison of Two Different Brands of Modified-Release Oral Dosage Forms Regarding Safety and Efficacy in Children With Attention Deficit Hyperactivity Disorder (ADHD) Aged 6 - 14

Start: Oct 2005Est. completion: Feb 2006130 patients

Phase 3Completed

NCT00228540 TevaModafinil

Study to Assess Satisfaction With Modafinil Treatment in Children and Adolescents With ADHD

Start: Sep 2005Est. completion: Sep 2006

Phase 3Completed

NCT00141063 SandozFocalin XR

Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD

Start: Jun 2005Est. completion: Aug 200590 patients

Phase 3Completed

NCT00141050 SandozFocalin XR

Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD

Start: May 2005Est. completion: Jul 200590 patients

Phase 3Completed

NCT05683249 NeurocentriaNRCT-101-SR

Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD)

Start: Feb 2023Est. completion: Jan 2024223 patients

Phase 2/3Completed

NCT06673368 NeurocentriaNRCT-101SR, NRCT-202XR

A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT-202XR Alone in Subjects With Attention-Deficit/Hyperactivity Disorder

Start: Feb 2025Est. completion: Jul 20252 patients

Phase 2Terminated

NCT05219370 BiocorpCannabis oil

Treatment With Cannabis Oil Containing CBD, THC, CBDV or CBG vs. Placebo of Persons With ADHD

Start: Jul 2022Est. completion: Dec 20228 patients

Phase 2Terminated

NCT07314333 OtsukaCentanafadine

A Trial to Assess How Centanafadine Interacts With Stimulants in the Body

Start: Feb 2026Est. completion: Apr 202642 patients

Phase 1Recruiting

NCT03292848 OtsukaBrexpiprazole

Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders

Start: Oct 2017Est. completion: May 201824 patients

Phase 1Completed

NCT01924143 Theravance BiopharmaTD-9855

TD-9855 Mass Balance Study

Start: Oct 2013Est. completion: Dec 20136 patients

Phase 1Completed

NCT01183234 TakedaSPD544

SPD544 High Strength Bioequivalence Study

Start: Aug 2010Est. completion: Oct 201028 patients

Phase 1Completed

NCT06639139 Jerusalem PharmaceuticalsCogFun RG occupational therapy

The Effectiveness of Cognitive-Functional Remote Group Intervention (Cog-Fun RG) for Adults with Attention Deficit Hyperactivity Disorder (ADHD)

Start: Nov 2024Est. completion: Feb 202640 patients

N/ARecruiting

NCT06766214 Soomatranscranial direct current stimulation

Attexis and tDCS for the Treatment of ADHD

Start: Sep 2024Est. completion: Feb 202630 patients

N/ACompleted

NCT06036420 Angeles TherapeuticsFlashed Light Therapy

Flashed Light Therapy for Adolescents With ADHD and Delayed Sleep Timing

Start: Oct 2023Est. completion: Mar 20276 patients

N/AActive Not Recruiting

NCT05805176 Lumos PharmaADHD Therapy

An Adjunct Study to Assess Guided ADHD Therapy for Managing the Extent and Severity of Symptoms

Start: Apr 2023Est. completion: Jun 2025194 patients

N/AActive Not Recruiting

NCT06303674 Innovation PharmaceuticalsPhysical activity with engaging cognitively

Effects of Brain Breaks on Educational Achievement in Laboratory Settings: The Break4Brain Project

Start: Feb 2023Est. completion: Sep 202560 patients

N/AUnknown

NCT05296473 Lumos PharmaADHD Therapy

Guided ADHD Therapy for Managing the Extent and Severity of Symptoms

Start: May 2022Est. completion: Mar 2024560 patients

N/ACompleted

NCT04497363 Angeles TherapeuticsBrainsonix Pulsar 1002

Focused Ultrasound for the Treatment of ADHD Symptoms

Start: Jul 2020Est. completion: Mar 2026100 patients

N/AUnknown

NCT03104972 Jerusalem PharmaceuticalstDCS

Non-invasive Brain Stimulation for Pediatric ADHD

Start: Feb 2018Est. completion: Jan 202247 patients

N/ACompleted

NCT03154359 Human BioSciencesAtomoxetine Hydrochloride

Atomoxetine PBPK-PD Clinical Study

Start: Dec 2017Est. completion: Jun 202251 patients

N/ACompleted

NCT00540826 Prevail TherapeuticsAtomoxetine

Treatment Compliance in Children and Adolescents on ADHD Medication

Start: Nov 2007Est. completion: Jun 2009518 patients

N/ACompleted

NCT00046059 Human BioSciencesGenetic Analysis of Attention Deficit Hyperactivity Disorder (ADHD)

Genetic Analysis of Attention Deficit Hyperactivity Disorder (ADHD)

Start: Feb 2000Est. completion: Jan 20203,481 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

10 late-stage (Phase 3) programs, potential near-term approvals

4 actively recruiting trials targeting 9,830 patients

24 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.